Characterization of Opa interacting protein 5 as a new biomarker and therapeutic target for oral cancer
Ming Zhu(AbbVie (United States)), Yataro Daigo(The University of Tokyo), Bayarbat Tsevegjav(Shiga University of Medical Science), Masanori Shinohara(Kumamoto University), Atsushi Takano(The University of Tokyo), Yoshihiro Yoshitake(Kumamoto University)
Cited by 6
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
HJURP Is a Cell-Cycle-Dependent Maintenance and Deposition Factor of CENP-A at Centromeres
|Cell|2009|636
Mutations truncating the EP300 acetylase in human cancers
|Nature Genetics|2000|593